… molecularly targeted agents of advanced gastric cancer and review emerging targeted therapies
… The goal is that a better understanding of the molecular landscape of gastric cancer will …

… Gastric cancer (GC) represents a leading cause of cancer … In the last decade, the development
of targeted therapies and … The Cancer Genome Atlas and the Asian Cancer Research …

… In recent years, although the incidence and mortality of gastric cancer are decreasing, …
cancer medicine entering into clinical practice, the molecular targeted therapy of gastric cancer …

… , we will likely be able to truly personalize therapy selection, offering targeted therapies with
… Newer therapies may allow us to offer HER2-targeted therapies to patients with lower HER2 …

… months) in treatment-refractory gastric cancer and is now an approved third-line regimen.
The role of immunotherapy and targeted therapies in gastric cancer is discussed further below, …

… the emergence of new immunotherapy and targeted therapies for patients at various stages
… gastric cancer. We also discuss the developments in immunotherapy and targeted therapy …

… promotes the development of targeted drug resistance. … gastric cancer-targeted therapy. In
addition, the research status of drug resistance in molecule-targeted therapy of gastric cancer …

… Targeted therapies licensed to treat gastric cancer include trastuzumab (HER2-positive
patients first line), ramucirumab (anti-angiogenic second line), and nivolumab or pembrolizumab …

… gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data
of clinical trial incorporating targeted … of research on targeted therapy for advanced GC. …

… Additionally, combination therapies with other modalities, such as targeted therapies, are …
ICIs and targeted therapy alone or combination with existing therapies gastric cancer treatment …